Hospital

In an interview with Pharmacy Times, Robin Tumlinson, PharmD, BCOP, clinical pharmacist specialist in genitourinary oncology at Vanderbilt University Medical Center, discussed recent developments reshaping bladder cancer treatment across disease stages.

The approval is supported by data from the phase 3 FINE-ONE clinical trial.

As centanafadine awaits DEA scheduling, Megan Maroney, PharmD, BCPP, FAAPP, and Danielle Stutzman, PharmD, BCPP, unpack what its modest efficacy data, favorable interaction profile, and pediatric dosing considerations mean for real-world ADHD prescribing.

Maroney and her guest, Danielle Stutzman, PharmD, BCPP, break down efficacy data and potential advantages of centanafadine, the newly approved triple reuptake inhibitor for ADHD.

The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.

Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

In an interview with Pharmacy Times, Carole R. Berini, PhD, research scientist at Ontada, and Saamir Pasha, MPH, senior biostatistician at Ontada, discussed how validated proxies for missing Eastern Cooperative Oncology Group (ECOG) performance status could strengthen real-world oncology evidence.

Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.

In an interview with Pharmacy Times, Carole R. Berini, PhD, research scientist at Ontada, and Saamir Pasha, MPH, senior biostatistician at Ontada, discussed how artificial intelligence and routinely collected clinical data could help address missing Eastern Cooperative Oncology Group (ECOG) performance status in real-world oncology research.

Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.

Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.

The expanded approval of leniolisib makes it the first approved treatment for pediatric patients with activated phosphoinositide 3-kinase delta syndrome.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Long-term use of PPIs—and, to a lesser degree, histamine 2 receptor antagonists—may increase the risk of bacterial infections, including C difficile and pneumonia, underscoring the need for pragmatic prescribing.

Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.

The data support GPRC5D-directed CAR T-cell therapy as a potential option following prior BCMA-targeted treatment.

Investing in formalized technician education not only supports competency development but also strengthens workforce stability.

The DAPA ACT HF-TIMI 68 analysis shows early, sustained congestion relief and rising diuretic efficiency through 2 months.

The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.

The investigational IL-33–targeting monoclonal antibody tozorakimab reduced moderate to severe COPD exacerbations across two phase 3 trials, including among patients with low blood eosinophil counts.